Good morning :)
$
₹
Kymera Therapeutics Inc

Kymera Therapeutics Inc

KYMR

NASDAQ
Asset Logo

Kymera Therapeutics Inc

KYMR

NASDAQ
$116.410.83% (-0.98)
$
₹
$116.410.83% (-0.98)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $9.8B the stock is ranked 1012

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

6.45
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-3.25
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-285.33%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 20 analysts' reports

Buy
17 analysts
Hold
3 analysts
Sell
0 analyst

Analysts expect a +15.87% price upside over the next year

Current Price$116.41
Target Price$134.95

Company Profile

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
72.44
72.44
1Y Return
23.12%
23.12%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.17
27.17
1Y Return
57.16%
57.16%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
31.2%
31.2%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
31.84
31.84
1Y Return
33.81%
33.81%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.49
20.49
1Y Return
45.28%
45.28%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Kymera Therapeutics Inc -6.45-
AbbVie Inc72.4450.450.37
Amgen Inc27.1720.542.13

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

2.7
-82.1
2.8
-87
34.3
-69.2
65
-61.2
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue10.2825.653.747.3922.111.472.762.8634.3665
Net Income-48.55-42.06-62.48-70.75-65.58-76.61-82.17-87.03-69.23-61.21
Net Profit Margin-472.02%-163.98%-1670.32%-956.88%-296.74%-667.60%-2973.04%-3043.00%-201.46%-94.17%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Kymera Therapeutics Inc (KYMR) share price today is $116.41 as of September 9, 2026 at 1:30 AM IST. The stock touched a day high of $120.31 and a day low of $114.92.

  2. Kymera Therapeutics Inc stock trades on NASDAQ under the ticker symbol KYMR.

  3. Kymera Therapeutics Inc's market capitalization is $9.76B as of September 9, 2026 at 1:30 AM IST.

  4. Kymera Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of September 8, 2026.

  5. Kymera Therapeutics Inc's price-to-book (P/B) ratio is 6.45 as of September 8, 2026.

  6. Yes, You can buy Kymera Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Kymera Therapeutics Inc shares in three steps: 1. Search Kymera Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Kymera Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Kymera Therapeutics Inc (KYMR) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0859 shares at the current price of $116.41.

Loading...